Exploring Changes in SDTMIG 3.4 & ADaMIG 1.3
On November 29th 2021, CDISC released updated versions of SDTM and ADaM, including standardized structures…
CertaraDecember 16, 2021
A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease
New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…
CertaraDecember 15, 2021
Certara Announces Release of Pinnacle 21 Enterprise Software
New metrics and analytics capabilities enable informed decision making for biopharmaceutical clients PRINCETON, N.J., Dec.…
CertaraDecember 13, 2021
Predicting and Taming Immunogenicity: Strategies for your Biologic Drug
Immunogenicity is the ability of a foreign substance, such as a drug or vaccine, to…
CertaraNovember 19, 2021
Accelerating the establishment of precision medicine using PK-PD/TD modeling
Certara’s Japan team first met Dr. Kobuchi when he was studying Pharmacometrics at university for…
CertaraNovember 18, 2021
Dose Optimization Using Population PK for an Orphan Drug
RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…
CertaraNovember 17, 2021
Industry Metrics for CDISC Controlled Terminology
Sergiy Sirichenko summarizes industry metrics across many studies and sponsors to produce an overall picture…
CertaraNovember 17, 2021
